Oncological features and prognosis of colorectal cancer in human immunodeficiency virus-positive patients: A retrospective study

Table 1 Comparison of baseline data before and after propensity score matching

	Before PSM			After PSM
	HIV-negative (n = 363)	HIV-positive (n = 24)	P value	HIV-negative (n = 48)	HIV-positive (n = 24)	P value
Sex			1			1
Male	211 (58.1)	14 (58.3)		29 (60.4)	14 (58.3)
Female	152 (41.9)	10 (41.7)		19 (39.6)	10 (41.7)
Age (yr)	66.3 ± 10.6	63.6 ± 12.0	0.283	64.3 ± 12.4	63.6 ± 12.0	0.808
Tumor			0.466			0.833
Proximal colon	126 (34.7)	7 (29.2)		11 (22.9)	7 (29.2)
Distal colon	101 (27.8)	5 (20.8)		10 (20.8)	5 (20.8)
Rectum	136 (37.5)	12 (50.0)		27 (56.2)	12 (50.0)
Degree of differentiation			0.572			1
Low	36 (9.9)	3 (12.5)		6 (12.5)	3 (12.5)
Moderate	316 (87.1)	20 (83.3)		40 (83.3)	20 (83.3)
High	11 (3.0)	1 (4.2)		2 (4.2)	1 (4.2)
Tumor stage			0.425			1
T1	18 (5.0)	0 (0.0)		0 (0.0)	0 (0.0)
T2	53 (14.6)	6 (25.0)		13 (27.1)	6 (25.0)
T3	200 (55.1)	13 (54.2)		25 (52.1)	13 (54.2)
T4a	73 (20.1)	3 (12.5)		7 (14.6)	3 (12.5)
T4b	19 (5.2)	2 (8.3)		3 (6.2)	2 (8.3)

¹The tumor sites of colorectal cancer were classified as proximal colon (ICD-O3C180-84), distal colon (ICD-O3C185-87), and rectum (ICD-O3C199, C209) according to the International Classification of Diseases in Oncology.

Variables are expressed as median (P25, P75) or n (%). PSM: Propensity score matching; HIV: Human immunodeficiency virus; T: Tumor.